Skip to main content

Significant investments

Typically, building a strategic position begins by investing in a private company with development potential and expands at follow-on financing rounds as well as IPOs.

HBM Healthcare is committed to broad diversification according to the following parameters: private and public companies; development phase; therapeutic area; geography; company size (market capitalisation, valuation). Without the Board of Directors' approval, the acquisition value of an investment may not exceed 10 percent of net assets.

Overview as at 30 June 2023

CHF
316
million
Shanghai Cathay Biotech
CHF
162
million
Swixx BioPharma
Harmony Biosciences
CHF
68
million
Neurelis
CHF
50
million
CHF
50
million
Fangzhou (Jianke)
CHF
47
million
ConnectRN
Mineralys Therapeutics
CHF
44
million